IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 775 
Supporting the designation of September 2025 as ‘‘National Ovarian Cancer 
Awareness Month’’. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 30, 2025 
Ms. DELAURO (for herself and Mr. BACON) submitted the following resolu-
tion; which was referred to the Committee on Oversight and Government 
Reform 
RESOLUTION 
Supporting the designation of September 2025 as ‘‘National 
Ovarian Cancer Awareness Month’’. 
Whereas ovarian cancer is the fifth-leading cause of cancer 
deaths of women in the United States and causes more 
deaths than any other gynecologic cancer; 
Whereas, in the United States, a woman’s lifetime risk of 
being diagnosed with ovarian cancer is about 1 in 91; 
Whereas the American Cancer Society estimates 20,890 cases 
of ovarian cancer will be newly diagnosed in 2025, and 
12,730 individuals will die from the disease nationwide; 
Whereas the 5-year survival rate for ovarian cancer is 51.6 
percent, and survival rates vary greatly depending on the 
stage of diagnosis; 
VerDate Sep 11 2014 
00:15 Oct 01, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR775.IH
HR775
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 775 IH 
Whereas the 5-year survival rate for ovarian cancer is over 
90 percent for individuals diagnosed in early stages; 
Whereas, while the mammogram can detect breast cancer and 
the pap smear can detect cervical cancer, there is no reli-
able early detection test for ovarian cancer; 
Whereas, in June 2007, the first national consensus state-
ment on ovarian cancer symptoms was developed to pro-
vide consistency in describing symptoms to make it easier 
for women to learn and remember those symptoms; 
Whereas Black women with ovarian cancer are more likely to 
have late-stage diagnoses, receive lower quality clinical 
services, and have lower 5-year survival rates than non- 
Black women; 
Whereas Black women have a 5-year ovarian cancer mortality 
rate of 62 percent, while the 5-year ovarian cancer mor-
tality rate is 54 percent for White women; 
Whereas women of color, low-income women, and women liv-
ing in rural areas have more barriers to accessing a 
standard quality of care and are more likely to receive 
care at a facility that has poorer adherence to National 
Comprehensive Cancer Network treatment guidelines; 
Whereas the proportion of ovarian cancer cases in women 
serving on Active Duty who are less than 45 years of age 
is substantially greater than in the general population; 
Whereas too many people remain unaware that the symptoms 
of ovarian cancer often include bloating, pelvic or abdom-
inal pain, difficulty eating or feeling full quickly, urinary 
symptoms, and several other vague symptoms that are 
often easily confused with other diseases; 
VerDate Sep 11 2014 
00:15 Oct 01, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR775.IH
HR775
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 775 IH 
Whereas improved awareness of the symptoms of ovarian 
cancer by the public and health care providers can lead 
to quicker diagnoses and more treatment opportunities; 
Whereas the lack of an early detection test for ovarian cancer 
combined with its vague symptoms mean that approxi-
mately 80 percent of cases of ovarian cancer are detected 
at an advanced stage; 
Whereas issues collecting and reporting data on treatment 
and outcomes related to ovarian cancer risk, especially 
for underserved communities and marginalized popu-
lations, can impede the development of effective policy; 
Whereas all women are at risk for ovarian cancer, but ap-
proximately 20 percent of women who are diagnosed with 
ovarian cancer have a hereditary predisposition to ovar-
ian cancer, which places them at even higher risk; 
Whereas scientists and physicians have uncovered changes in 
the BRCA genes that some women inherit from their 
parents, which may make those women 30 times more 
likely to develop ovarian cancer; 
Whereas the family history of a woman has been found to 
play an important role in accurately assessing her risk of 
developing ovarian cancer, and medical experts believe 
that family history should be taken into consideration 
during the annual well-woman visit of any woman; 
Whereas those women who have a family history of ovarian 
or breast cancer should consider genetic testing and 
counseling to determine whether their risk of developing 
a heritable cancer is elevated; 
Whereas women who know that they are at high risk of ovar-
ian cancer may undertake prophylactic measures like an 
VerDate Sep 11 2014 
00:15 Oct 01, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR775.IH
HR775
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 775 IH 
opportunistic salpingectomy to help reduce the risk of de-
veloping this disease; 
Whereas guidelines issued by the National Comprehensive 
Cancer Network and the Society of Gynecologic Oncology 
recommend that all individuals diagnosed with ovarian 
cancer receive genetic counseling and genetic testing re-
gardless of their family history; 
Whereas studies consistently show that compliance with these 
guidelines is alarmingly low, with recently published Na-
tional Cancer Institute-funded research finding that in 
2013 and 2014, only one-third of ovarian cancer sur-
vivors have undergone such testing; 
Whereas, according to a 2016 consensus report by the Na-
tional Academy of Medicine, ‘‘there remain surprising 
gaps in the fundamental knowledge about and under-
standing of ovarian cancer’’ across all aspects of the dis-
ease; 
Whereas ovarian cancer research remains underfunded rel-
ative to its mortality rate, making increased Federal in-
vestment critical to progress; 
Whereas ongoing investments in ovarian cancer research and 
education and awareness efforts are critical to closing 
these gaps and improving survivorship for women with 
ovarian cancer; 
Whereas, each year during the month of September, the 
Ovarian Cancer Research Alliance and community part-
ner organizations hold a number of events to increase 
public awareness of ovarian cancer and its symptoms; 
and 
VerDate Sep 11 2014 
00:15 Oct 01, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6300
E:\BILLS\HR775.IH
HR775
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 775 IH 
Whereas September 2025 should be designated as ‘‘National 
Ovarian Cancer Awareness Month’’ to increase public 
awareness of ovarian cancer: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) supports the designation of ‘‘National Ovar-
ian Cancer Awareness Month’’; and 
(2) supports the goals and ideals of ‘‘National 
Ovarian Cancer Awareness Month’’. 
Æ 
VerDate Sep 11 2014 
00:15 Oct 01, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR775.IH
HR775
ssavage on LAPJG3WLY3PROD with BILLS